Sunshine Biopharma Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.7K | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | — | — | — | — | — | — | — |
| Gross Profit | $0 | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $0 | $32.8K | $8.7K | $327.0K | $137.4K | $1.8K | $142.7K | $0 |
| SG&A Expense | $857.2K | $993.1K | $782.0K | $1.8M | $1.9M | $706.7K | $556.2K | $537.4K |
| Operating Income | $-857.2K | $-993.1K | $-780.3K | $-1.8M | $-1.9M | $-706.7K | $-556.2K | — |
| Operating Margin | — | — | -45,683.7% | — | — | — | — | — |
| Interest Expense | $104.8K | $34.7K | $307.2K | $140.9K | $6.5K | $1.3K | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-1.0M | $-3.5M | $-1.7M | $-1.9M | $-2.5M | $-708.0K | $-556.2K | $-537.4K |
| Net Margin | — | — | -96,774.5% | — | — | — | — | — |
| EPS (Basic) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | — | — | — | — | — | — | — | — |
| Shares Outstanding (Basic) | 119.38B | 1.16T | 1.00T | 542.81B | 454.69B | 408.55B | 253.48B | 245.06B |
| Shares Outstanding (Diluted) | 119.38B | 1.16T | 1.00T | 542.81B | 454.69B | 408.55B | 253.48B | 245.06B |
| Dividends Per Share | — | — | — | — | — | — | — | — |